SCA
MDCO

SAC Capital Advisors’s Medicines Co MDCO Stock Holding History

SAC Capital Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-140,000
Closed -$4.31M – 2017
2013
Q2 		$4.31M Buy
+140,000
New +$4.68M 0.02% 557

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAC
Smith Affiliated Capital New York $86.5B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

SAC Capital Advisors's MDCO Position: Q4 2013 in Review

SAC Capital Advisors sold out of Medicines Co (MDCO) in Q4 2013, closing a stake of 148,033 shares — an estimated $4.96M sold.

SAC Capital Advisors first reported a position in MDCO in Q2 2013 and held it in 2 quarters. The position peaked at $8.64M in Q2 2013. 182 funds tracked by Wall St. Rank hold MDCO as of Q4 2013.

  • SAC Capital Advisors reported no remaining Medicines Co position as of Q4 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 148,033 Medicines Co shares in Q4 2013, an estimated $4.96M.
  • SAC Capital Advisors first reported a position in Medicines Co in Q2 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Medicines Co position peaked at $8.64M in Q2 2013.
  • 182 funds tracked by Wall St. Rank held Medicines Co as of Q4 2013.

Based on SAC Capital Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.